Investigational Drug Information for Dalcetrapib
✉ Email this page to a colleague
What is the drug development status for Dalcetrapib?
Dalcetrapib is an investigational drug.
There have been 15 clinical trials for Dalcetrapib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Myocardial Ischemia, Heart Diseases, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche, The Montreal Health Innovations Coordinating Center (MHICC), and DalCor Pharmaceuticals.
There are seven hundred and twenty-eight US patents protecting this investigational drug and eight international patents.
Summary for Dalcetrapib
| US Patents | 728 |
| International Patents | 8,104 |
| US Patent Applications | 1,524 |
| WIPO Patent Applications | 846 |
| Japanese Patent Applications | 587 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 78 |
Recent Clinical Trials for Dalcetrapib
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | Covance | Phase 2 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | The Montreal Health Innovations Coordinating Center (MHICC) | Phase 2 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | DalCor Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Dalcetrapib
Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib
US Patents for Dalcetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dalcetrapib | See Plans and Pricing | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | See Plans and Pricing |
| Dalcetrapib | See Plans and Pricing | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| Dalcetrapib | See Plans and Pricing | Compounds useful for the treatment of metabolic disorders and synthesis of the same | North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) | See Plans and Pricing |
| Dalcetrapib | See Plans and Pricing | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | See Plans and Pricing |
| Dalcetrapib | See Plans and Pricing | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | Merck Sharp & Dohme Corp. (Rahway, NJ) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dalcetrapib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dalcetrapib | Australia | AU2011326871 | 2030-11-08 | See Plans and Pricing |
| Dalcetrapib | Brazil | BR112013010157 | 2030-11-08 | See Plans and Pricing |
| Dalcetrapib | Canada | CA2815749 | 2030-11-08 | See Plans and Pricing |
| Dalcetrapib | China | CN103260625 | 2030-11-08 | See Plans and Pricing |
| Dalcetrapib | China | CN105288580 | 2030-11-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
